Mehta Analysis: Biopharma's 10% Myth
Executive Summary
Viren Mehta, founder of Mehta Partners, LLC, considers the oft-repeated statement that the cost of drugs represents only 10% of US healthcare expenditure. Does it matter that the figure excludes a large and growing segment of medicine spending?
You may also be interested in...
Sanofi's Drug Pricing Pledge Ties Increases To National Health Expenditure
While other companies have promised not to raise their drug prices beyond 10%, Sanofi is using the rate of medical inflation (expected to be 5.4% in 2017) in setting its annual list price hikes. Company retains option to increase prices beyond benchmark.
Drug Pricing: CMS Seeing ‘Too Many Examples’ Of Excessive Increases
Acting Administrator Slavitt says big prescription drug price increases are a widespread practice and controlling drug costs ‘is likely to be a big priority’ for next head of CMS.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.